Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer

ObjectiveThe TOPAZ-1 trial reported a significant survival benefit of durvalumab in combination with chemotherapy for the first-line treatment of biliary tract cancer (BTC). However, no studies have evaluated the economics of this treatment option. The aim of this study was to assess the cost effect...

Full description

Bibliographic Details
Main Authors: Zhuo-miao Ye, Zhe Xu, Huan Li, Qian Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Public Health
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fpubh.2023.1046424/full